NCT04136366Phase 3Completed

The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

Study sponsor: Aldeyra Therapeutics, Inc. · ALDX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2022-06-14Actual
Enrollment · participants106Actual
Source updated2025-07-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview